IIT Indore Unveils AI Digital Twin Charak DT for Early Disease Detection
On January 15, 2026, researchers at the Indian Institute of Technology (IIT) Indore introduced an innovative AI-powered digital twin named Charak DT, designed for early disease detection and preventive diagnosis. This groundbreaking technology was unveiled during the Madhya Pradesh Regional AI Impact Conference 2026 held in Bhopal.
What is Charak DT?
Charak DT is a sophisticated simulation that replicates physiological functions such as breathing and blinking, allowing researchers to study the progression of diseases across various organs. The platform is named after the ancient Indian medical text, the Charaka Samhita, which emphasizes the importance of understanding the human body in the context of health and disease.
How Does Charak DT Work?
The digital twin creates a virtual replica of patients, enabling medical experiments that can test treatments without putting real subjects at risk. This innovative approach allows for the safe virtual trials of medicines and therapies, making it a significant advancement in medical research.
Focus on Lung Simulations
Currently, Charak DT is primarily focused on lung simulations. It has been trained on human parameters that trigger diseases, allowing it to diagnose conditions when specific parameters exceed predetermined thresholds. Vaibhav Jain, a representative from Drishti CPS, the technology innovation hub at IIT Indore, explained, “We are making a digital twin of the human body which aims to provide preventive diagnosis.”
Clinical Trials and Validation
To ensure the effectiveness of Charak DT, clinical validation is set to begin soon through partnerships with three All India Institute of Medical Sciences (AIIMS) facilities: AIIMS Bhopal, AIIMS Delhi, and AIIMS Raipur. These trials will assess the platform’s accuracy in real-world diagnostics, marking a pivotal step towards broader adoption in the medical field.
Collaboration with AIIMS
- AIIMS Bhopal: Involved in initial trials and validation of the technology.
- AIIMS Delhi: A key partner for expanding research and application of Charak DT.
- AIIMS Raipur: Participating in clinical studies to evaluate the platform’s diagnostic capabilities.
Drishti CPS and Its Role
Charak DT has been developed by Drishti CPS, a technology innovation hub at IIT Indore that is funded by the Department of Science and Technology under the National Mission on Interdisciplinary Cyber-Physical Systems (NM-ICPS). This hub has already supported 89 startups across various sectors, with a current focus on healthcare solutions.
Future Plans and Expansion
Looking ahead, the development team plans to expand the capabilities of Charak DT beyond lung simulations. Future iterations may include digital twins for cardiovascular health and other organ systems, enhancing the platform’s utility in preventive medicine.
Benefits of AI in Healthcare
The introduction of AI technologies like Charak DT presents numerous benefits for the healthcare sector:
- Early Disease Detection: By simulating human physiology, the platform can identify potential health issues before they become critical.
- Cost-Effective Trials: Virtual trials reduce the need for extensive human testing, saving time and resources.
- Enhanced Research Capabilities: Researchers can explore various treatment options without the ethical concerns associated with traditional clinical trials.
- Personalized Medicine: Digital twins can be tailored to individual patients, potentially leading to more effective treatment plans.
Conclusion
The unveiling of Charak DT at IIT Indore marks a significant milestone in the intersection of artificial intelligence and healthcare. By creating a digital twin of the human body, researchers aim to revolutionize early disease detection and preventive diagnosis, ultimately improving patient outcomes. As clinical trials commence, the potential for this technology to transform medical practices is immense, paving the way for a future where AI plays an integral role in healthcare.
Note: The information presented in this article is based on current research and developments as of January 2026.
